Vitamin D to prevent COVID-19 or other acute respiratory infections: phase 3 randomised controlled trial (CORONAVIT)
D. Jolliffe (London, United Kingdom), H. Holt (London, United Kingdom), M. Talaei (London, United Kingdom), A. Sheikh (Edinburgh, United Kingdom), C. Griffiths (London, United Kingdom), S. Shaheen (London, United Kingdom), C. Relton (London, United Kingdom), A. Martineau (London, United Kingdom)
Source: International Congress 2022 – What's new in COVID
Session: What's new in COVID
Session type: Oral Presentation
Number: 3795
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Jolliffe (London, United Kingdom), H. Holt (London, United Kingdom), M. Talaei (London, United Kingdom), A. Sheikh (Edinburgh, United Kingdom), C. Griffiths (London, United Kingdom), S. Shaheen (London, United Kingdom), C. Relton (London, United Kingdom), A. Martineau (London, United Kingdom). Vitamin D to prevent COVID-19 or other acute respiratory infections: phase 3 randomised controlled trial (CORONAVIT). 3795
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|